BioXcel Therapeutics Inc Q3 2020 Earnings Call Transcript - Thomson StreetEvents

BioXcel Therapeutics Inc Q3 2020 Earnings Call Transcript

BioXcel Therapeutics Inc Q3 2020 Earnings Call Transcript - Thomson StreetEvents
BioXcel Therapeutics Inc Q3 2020 Earnings Call Transcript
Published Nov 12, 2020
Published Nov 12, 2020
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of BTAI.OQ earnings conference call or presentation 12-Nov-20 1:30pm GMT

  
Report Type:

Transcript

Source:
Company:
BioXcel Therapeutics Inc
Ticker
BTAI.OQ
Time
1:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : I have 3 questions, actually. The first one is on TRANQUILITY. If you do decide to go to another cohort, how can you help frame what that means for investors? Because the only real conclusion that might be able to be drawn is that the prior highest dose is safe enough for you to be comfortable REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. NOVEMBER 12, 2020 / 1:30PM, BTAI.OQ - Q3 2020 BioXcel Therapeutics Inc Earnings Call to proceed. So any thoughts on how the company might be able to take an interim look at efficacy in the fourth quarter as you move on to the next dose? That's the first question.


Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : Got it. And then I'll ask the next 2 questions upfront. So if you move to chronic treatment of agitation in dementia, could you comment on the potential for any cognitive upsides or downsides of dex in the geriatric patient population? And on 701, there were some very intriguing data at SITC recently. Now that the triple combo is not proceeding, what are your priorities for your next indication other than prostate cancer?

Table Of Contents

BioXcel Therapeutics Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript – 2021-05-11 – US$ 54.00 – Edited Transcript of BTAI.OQ presentation 11-May-21 12:45pm GMT

BioXcel Therapeutics Inc Q1 2021 Earnings Call Transcript – 2021-05-10 – US$ 54.00 – Edited Transcript of BTAI.OQ earnings conference call or presentation 10-May-21 12:30pm GMT

BioXcel Therapeutics Inc Q4 2020 Earnings Call Transcript – 2021-03-11 – US$ 54.00 – Edited Transcript of BTAI.OQ earnings conference call or presentation 11-Mar-21 1:30pm GMT

BioXcel Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript – 2021-01-14 – US$ 54.00 – Edited Transcript of BTAI.OQ presentation 14-Jan-21 1:20pm GMT

BioXcel Therapeutics, Inc. - Special Call Transcript – 2021-01-05 – US$ 54.00 – Edited Transcript of BTAI.OQ conference call or presentation 5-Jan-21 1:30pm GMT

BioXcel Therapeutics Inc Q2 2020 Earnings Call Transcript – 2020-08-14 – US$ 54.00 – Edited Transcript of BTAI.OQ earnings conference call or presentation 14-Aug-20 12:30pm GMT

BioXcel Therapeutics, Inc. - Special Call Transcript – 2020-07-20 – US$ 54.00 – Edited Transcript of BTAI.OQ conference call or presentation 20-Jul-20 12:30pm GMT

BioXcel Therapeutics Inc at Bank of America Merrill Lynch Napa Healthcare Conference (Virtual) Transcript – 2020-06-24 – US$ 54.00 – Edited Transcript of BTAI.OQ presentation 24-Jun-20 2:30pm GMT

BioXcel Therapeutics Inc Annual Shareholders Meeting Transcript – 2020-05-20 – US$ 54.00 – Edited Transcript of BTAI.OQ shareholder or annual meeting 20-May-20 1:00pm GMT

BioXcel Therapeutics Inc at UBS Global Healthcare Conference (Virtual) Transcript – 2020-05-18 – US$ 54.00 – Edited Transcript of BTAI.OQ presentation 18-May-20 8:40pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "BioXcel Therapeutics Inc Q3 2020 Earnings Call Transcript" Nov 12, 2020. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q3-2020-BioXcel-Therapeutics-Inc-Earnings-Call-T13477923>
  
APA:
Thomson StreetEvents. (2020). BioXcel Therapeutics Inc Q3 2020 Earnings Call Transcript Nov 12, 2020. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q3-2020-BioXcel-Therapeutics-Inc-Earnings-Call-T13477923>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.